ImmunityBio's recently approved cancer drug has plenty of momentum. However, valuation concerns and clinical and regulatory ...

Shares of Culver City-based ImmunityBio Inc. surged yet again late last month to nearly a five-year high as its immunotherapy ...

ImmunityBio recently reported full-year 2025 results showing revenue rising to US$113.29 million while net loss narrowed to US$351.4 million, driven largely by the commercial rollout of ANKTIVA and ...

ImmunityBio's stock has roughly quintupled so far in 2026 as the company continues to deliver good news for investors.

ImmunityBio Inc. IBRX shares are trading lower on Monday. The company announced the resubmission of its supplemental Biologics License Application (sBLA) for ANKTIVA to the FDA. FDA Resubmission The ...

ImmunityBio, Inc. (NASDAQ:IBRX) is among the 12 Best Performing Stocks in February. On March 4, 2026, Piper Sandler analyst Patrick Soon-Shiong increased ImmunityBio, Inc. (NASDAQ:IBRX)’s price ...

ImmunityBio Inc. IBRX shares are up during Thursday’s premarket session as the company has completed enrollment in its ...

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of its supplemental Biologics License ...

Despite reporting explosive commercial growth and securing a critical regulatory filing, shares of ImmunityBio have come under significant selling pressure, shedding approximately 20% of their value ...

Biotechnology firm ImmunityBio has formally resubmitted its application to the U.S. Food and Drug Administration (FDA) for its lead therapy, ANKTIVA. This move follows an initial regulatory setback ...

ImmunityBio Inc. IBRX shares are up on Monday following the company’s announcement of significant revenue growth. • ...

ImmunityBio (NASDAQ:IBRX), which develops immunotherapies and vaccines for cancers and infectious diseases, closed Wednesday at $8.54, up 41.86%. The stock jumped after the European Commission granted ...